SU477580A3 - The method of cleaning serum - Google Patents
The method of cleaning serumInfo
- Publication number
- SU477580A3 SU477580A3 SU1186878A SU1186878A SU477580A3 SU 477580 A3 SU477580 A3 SU 477580A3 SU 1186878 A SU1186878 A SU 1186878A SU 1186878 A SU1186878 A SU 1186878A SU 477580 A3 SU477580 A3 SU 477580A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- serum
- rpm
- hours
- cleaning
- silicic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
Description
гируют, облучают ультрафиолетовыми лучами и стерильно фильтруют. После четырехнедельного хранени при 5°С отфильтровывают от случайно образовавшегос незначительного осадка.guarded, irradiated with ultraviolet rays and sterile filtered. After four weeks of storage at 5 ° C, a slight precipitate is formed by accident.
Пример 4. 1 л человеческой АСД-сыворотки устанавливают на 5,5% нротеина н при значении рН 6,5 хорошо смешивают с коллоидной кремниевой кислотой 4 ч при комнатной температуре и затем 4 ч нагревают при 45°С. После охлаждени центрифугируют 30 мин при 5000 об/мин, облучают ультрафиолетовыми лучами и стерильно фильтруют. После четырехчасового хранеии при 5°С отфильтровывают от случайно образовавшегос осадка.Example 4. One liter of human ASD serum is adjusted to 5.5% nrotein n at pH 6.5 and is well mixed with colloidal silicic acid for 4 hours at room temperature and then heated for 4 hours at 45 ° C. After cooling, the mixture is centrifuged for 30 minutes at 5000 rpm, irradiated with ultraviolet rays, and sterile filtered. After four hours of storage at 5 ° C, the precipitate formed at random is filtered.
Пример 5. 1 л цитратной плазмы (протеин: 5,0%, рН 7,5) размешивают с 20 г аэрозила 380 при 45°С в течение 4 ч. Центрифугируют в течение 20 мин нри 5000 об/мин н сливают верхнюю фазу.Example 5. 1 l citrate plasma (protein: 5.0%, pH 7.5) is stirred with 20 g of aerosil 380 at 45 ° C for 4 hours. Centrifuged for 20 minutes at 5000 rpm and the upper phase is drained.
Пример 6. 1 л плазмы (нротеин: 7,0, рН 7,6) размешивают с 20 г аэрозила 380 в течение 4 ч при 45°С. Центрифугируют в течение 20 мин при 5000 об/мин, сливают верхнюю фазу и стерильно фильтруют через фильтр типа Зейтц-EKS-l. Затем облучают адсорбированную сыворотку ультрафиолетовыми лучами .Example 6. 1 l of plasma (nrotein: 7.0, pH 7.6) is stirred with 20 g of aerosil 380 for 4 hours at 45 ° C. The mixture is centrifuged for 20 minutes at 5000 rpm, the upper phase is drained and sterile filtered through a Seitz-EKS-1 filter. Then the adsorbed serum is irradiated with ultraviolet rays.
Пример 7. 1 л человеческой сыворотки при значении рН 7 хорошо размешивают с 20 г стерилизованной гор чим воздухом коллоидной кремниевой кислоты в течение 3 ч при 30°С и после охлаждени центрифугируют в течение 30 .мин при 5000 об/мин, облучают ультрафиолетовыми лучами и фильтруют через фильтр из подход ш,его материала и с соответствуюш,им размером нор. По истечении четырехнедельного хранени при 5°С отфильтровывают случайно образовавшийс малый осадок.Example 7. 1 l of human serum at pH 7 was well stirred with 20 g of colloidal silicic acid sterilized with hot air for 3 hours at 30 ° C and, after cooling, centrifuged for 30 minutes at 5000 rpm, irradiated with ultraviolet rays and filter through the filter from the approach of w, its material and with the corresponding, the size of holes. After four weeks of storage at 5 ° C, a small precipitate that is formed is filtered by chance.
Пример 8. 1 л человеческой сыворотки при значении рН 7 хорошо размешивают с 20 г стерилизированной гор чим воздухом коллоидной кремниевой кислоты в течение 4 чExample 8. 1 l of human serum at pH 7 is well stirred with 20 g of hot air sterilized colloidal silicic acid for 4 hours
при 15°С н после охлаждени центрифугируют в течение 30 мин при 6000 об/мин, облучают ультрафиолетовыми лучами н фильтруют через фильтровые слои, содержащие асбест, непроницаемый дл бактерий, и с под.х:од ш,им размером пор. По истечении четырехнедельного хранени при 5°С отфильтровывают случайно образовавшийс малый осадок.after cooling at 15 ° C, centrifuged for 30 minutes at 6000 rpm, irradiated with ultraviolet rays, filtered through filter layers containing asbestos impermeable to bacteria, and with water: one, pore size. After four weeks of storage at 5 ° C, a small precipitate that is formed is filtered by chance.
Пример 9. Способ, приведенный в примере 8, повтор етс при 5°С, причем размешнвание продолжают б ч.Example 9. The method described in Example 8 is repeated at 5 ° C, with stirring being continued bh.
Употребл ема коллоидна кремниева кислота имеет следуюш,ие свойства;Colloidal silicic acid used has the following properties;
Насыпной вес 20-125 (предпочтительно 40-60) ,г/л.Bulk weight 20-125 (preferably 40-60), g / l.
Величина частиц 3-60 (предпочтительно ) ммк.The size of the particles 3-60 (preferably) MMK.
Удельна поверхность 100-500 (нредпочтительно 340-420) ..The specific surface area is 100-500 (preferably 340-420) ..
Коллоидную кремниевую кислоту смешивают с сывороткой посредством врандепи адсорбционных сосудов со скоростью (предпочтительно 30) об/мин; посредством размешивани при 10-50 (предпочтительно 30) об/мин.Colloidal silicic acid is mixed with serum by means of vrandepi adsorption vessels with a speed (preferably 30) rpm; by stirring at 10-50 (preferably 30) rpm.
Подход ш;ими вставными фильтрами вл ютс , нанример, целлюлозно-асбестовые фильтры с размерами пор 0,8-8 (предпочтительно 0,9-1,2) мк при фильтрационном давлении от 0,5 до 4 атмосфер. Кроме того, примен ют . мембранные фильтры е размерами пор от 0,05 до 0,5 (предпочтительно 0,2) мк при фильтрационном давлении 1-10 (предпочтительно 5) атмосфер.The approach is встав; these plug-in filters are, for example, cellulose-asbestos filters with a pore size of 0.8-8 (preferably 0.9-1.2) microns with a filtration pressure of from 0.5 to 4 atmospheres. In addition, apply. membrane filters with pore size from 0.05 to 0.5 (preferably 0.2) micron with a filtration pressure of 1-10 (preferably 5) atmospheres.
Предмет изобретени Subject invention
Способ очистки сыворотки путем обработки сорбентом, фильтрации и ультрафиолетового облучени , отличаюшийс тем, что, с целью повышени чистоты препарата, сыворотку соедин ют с коллоидной кремниевой кислотой в соотношении 250-500 мг на 1 г белка нри рН 6,5-8,0.The method of cleaning the serum by sorbent treatment, filtration and ultraviolet irradiation, characterized in that, in order to increase the purity of the preparation, the serum is combined with colloidal silicic acid in a ratio of 250-500 mg per 1 g of protein at pH 6.5-8.0.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEB0086560 | 1966-04-06 | ||
DE1966B0089704 DE1617335B2 (en) | 1966-11-05 | 1966-11-05 | PROCESS FOR MANUFACTURING LIPOPROTEIN-FREE, STABLE AND STERILE SERUM |
DEB0091011 | 1967-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SU477580A3 true SU477580A3 (en) | 1975-07-15 |
Family
ID=27209344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU1186878A SU477580A3 (en) | 1966-04-06 | 1967-09-29 | The method of cleaning serum |
Country Status (8)
Country | Link |
---|---|
US (1) | US3686395A (en) |
AT (1) | AT270868B (en) |
BE (1) | BE696020A (en) |
FR (1) | FR7395M (en) |
GB (1) | GB1115849A (en) |
NL (1) | NL6702923A (en) |
SE (1) | SE328089B (en) |
SU (1) | SU477580A3 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3822095A (en) * | 1972-08-14 | 1974-07-02 | Block Engineering | System for differentiating particles |
DE2364317C3 (en) * | 1973-12-22 | 1979-10-11 | Behringwerke Ag, 3550 Marburg | Procedure for the isolation of choleragen |
DK139056B (en) * | 1976-04-06 | 1978-12-11 | Nordisk Insulinlab | Method for recovering immunoglobulin suitable for intravenous administration. |
US4164495A (en) * | 1976-04-06 | 1979-08-14 | Nordisk Insulinlaboratorium | Method of recovering immunoglobulin using a polyol and an alkanoic acid |
US4136094A (en) * | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
JPS5446813A (en) * | 1977-09-22 | 1979-04-13 | Toyo Soda Mfg Co Ltd | Separation of plasmaprotein |
DE2837168A1 (en) * | 1978-08-25 | 1980-03-06 | Blutspendedienst Dt Rote Kreuz | METHOD FOR PRODUCING AN IMMUNAL GLOBULIN SOLUTION SUITABLE FOR INTRAVENOUS APPLICATION |
US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
US4378346A (en) * | 1979-08-15 | 1983-03-29 | Tankersley Donald L | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
US4251510A (en) * | 1979-08-15 | 1981-02-17 | Cutter Laboratories, Inc. | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
US4473647A (en) * | 1981-02-27 | 1984-09-25 | Amf Inc. | Tissue culture medium |
US4480029A (en) * | 1981-04-27 | 1984-10-30 | Baxter Travenol Laboratories, Inc. | Biological indicators and their use |
US4511473A (en) * | 1982-02-09 | 1985-04-16 | Amf Incorporated | Fibrous media containing millimicron-sized particulates |
US4578150A (en) * | 1982-07-23 | 1986-03-25 | Amf Inc. | Fibrous media containing millimicron-sized particulates |
DE3247150A1 (en) * | 1982-12-21 | 1984-06-28 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | CLOTHING ACTIVE PLASMA PROTEIN REDUCTION, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR TREATING DISORDERS OF THE HAEMOSTASE SYSTEM |
AU2492084A (en) * | 1983-01-26 | 1984-08-15 | Amf Inc. | Tissue culture medium |
US4533634A (en) * | 1983-01-26 | 1985-08-06 | Amf Inc. | Tissue culture medium |
US4639513A (en) * | 1984-02-02 | 1987-01-27 | Cuno Inc. | Intravenously injectable immunoglobulin G (IGG) and method for producing same |
DE3483751D1 (en) * | 1983-05-02 | 1991-01-31 | Diamond Scient Co | PHOTOCHEMICAL DISABLING TREATMENT OF FULL BLOOD OR BLOOD COMPONENTS. |
US4764369A (en) * | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4820805A (en) * | 1983-07-14 | 1989-04-11 | New York Blood Center, Inc. | Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives |
DE3330770A1 (en) * | 1983-08-26 | 1985-03-14 | Behringwerke Ag, 3550 Marburg | METHOD FOR PASTEURIZING HUMAN PLASMA |
US5418130A (en) * | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
NL9401535A (en) * | 1994-09-21 | 1996-05-01 | Stichting Scheikundig Onderzoe | Serum-prepared protein mixture for use as a component in media for in vitro culture of animal cells. |
AU2005229674B2 (en) * | 2004-11-18 | 2010-11-04 | Kedrion Melville Inc. | Low concentration solvent/detergent process of immuneglobulin with pre-treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2469193A (en) * | 1942-02-09 | 1949-05-03 | Research Corp | Protein fractionation |
US3284434A (en) * | 1960-08-29 | 1966-11-08 | Univ Kansas State | Protein isolation and preparations |
-
1967
- 1967-02-24 NL NL6702923A patent/NL6702923A/xx unknown
- 1967-03-07 GB GB10621/66D patent/GB1115849A/en not_active Expired
- 1967-03-17 AT AT258467A patent/AT270868B/en active
- 1967-03-23 BE BE696020D patent/BE696020A/xx unknown
- 1967-03-31 SE SE04492/67A patent/SE328089B/xx unknown
- 1967-04-05 FR FR101581A patent/FR7395M/fr not_active Expired
- 1967-09-29 SU SU1186878A patent/SU477580A3/en active
-
1970
- 1970-10-07 US US78949A patent/US3686395A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB1115849A (en) | 1968-05-29 |
NL6702923A (en) | 1967-10-09 |
BE696020A (en) | 1967-09-25 |
FR7395M (en) | 1969-11-03 |
AT270868B (en) | 1969-05-12 |
SE328089B (en) | 1970-09-07 |
US3686395A (en) | 1972-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU477580A3 (en) | The method of cleaning serum | |
Guo et al. | Hollow mesoporous carbon spheres—an excellent bilirubin adsorbent | |
US3470067A (en) | Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes | |
CA2796409A1 (en) | Process for preparing an immunoglobulin composition | |
US3608071A (en) | Manufacturing adsorbed vaccines | |
Sabin | Experiments on the purification and concentration of the virus of poliomyelitis | |
JPH04169539A (en) | Preventive and therapeutic agent for alimetary disease and production thereof | |
US5696236A (en) | Method for the removal of viruses from protein solutions | |
US10357512B2 (en) | Method for preparing universal plasma | |
ATE25690T1 (en) | PLASMA PROTEIN SOLUTION WITH ACTIVE COAGAGATION, PROCESS FOR ITS PREPARATION AND ITS USE IN THE TREATMENT OF DISORDERS OF THE HEMOSTASIS SYSTEM. | |
Humphries | Enzymic activity of bacteriophage-culture lysates: I. A capsule lysin active against Klebsiella pneumoniae type A | |
Bronfenbrenner | STUDIES ON THE BACTERIOPHAGE OF D'HERELLE: VII. On the Particulate Nature of Bacteriophage. | |
US3547779A (en) | Process for producing purified concentrated influenza virus | |
KR101164122B1 (en) | Device for Manufacturing Therapeutic Immunoglobulin Preparation and Manufacturing Methods Using Thereof | |
Tamauchi et al. | Enhancement of immunogenicity by incorporation of lipid A into liposomal model membranes and its application to membrane-associated antigens | |
Alexeyev et al. | Impaired neutrophil function in the cutaneous form of anthrax | |
US3840458A (en) | Process and apparatus for obtaining therapeutically active substances from animal tissue | |
CN107098966B (en) | Immunoglobulin and preparation method thereof | |
US4843065A (en) | Method of producing products for use in the treatment of bacterial and/or virus infections | |
Hunter et al. | Response of mice to rabbit Fab′ 2 and Fab′: Thymus independence of IgM response and thymus dependence of IgG response | |
Bauer et al. | Ultrafiltration of the virus of equine encephalomyelitis | |
McClung | On the staining of yeast spores | |
JPS606660B2 (en) | Method for manufacturing sterile artificial organs | |
CN107236038B (en) | Method for improving protein clarity by microcrystalline cellulose, and product and application thereof | |
JPH06277673A (en) | Silica containing apatite hydroxide bactericide and bactericidal treatment process |